NovaBridge Biosciences has 3 Schedule 13D or 13G filings on record since 2025-08-05. 2 holders' latest filing reports 5% or more of ordinary shares, par value $0.0001 per share (including ordinary shares underlying american depository shares). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Everest Medicines Limited | 16.1% | 42,524,716 | SCHEDULE 13D, 2025-08-05 | 2025-08-05 |
| CBC Investment I-Mab Limited | 11.5% | 11,784,164 | SCHEDULE 13D/A, 2026-02-03 | 2026-01-29 |
Purpose of Transaction (Item 4)
Everest Medicines Limited
The information set forth in or incorporated by reference in Item 3 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person purchased the aforementioned securities for investment purposes with the aim of increasing the value of its investments and the Issuer. Subject to applicable legal requirements, the Reporting Person may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Person's ownership of the Issuer's securities, other opportunities available to the Reporting Person, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Person may dispose of all or a portion of their securities of the Issuer at any time. The Reporting Person reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. Except as set forth in this Item 4 and Item 6 below, the Reporting Person does not have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Securities Exchange Act of 1934 (the "Act"). However, the Reporting Person reserves the right to propose or …The first part of Item 4 of the SCHEDULE 13D filed 2025-08-05; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Everest Medicines Limited | 16.1% | SCHEDULE 13D |
| 2025-08-07 | CBC Investment I-Mab Limited | 10.4% | SCHEDULE 13D/A |
| 2026-02-03 | CBC Investment I-Mab Limited | 11.5% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for NovaBridge Biosciences. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.